Design, synthesis and evaluation of novel ellipticine derivatives and analogues as anti-cancer agents

Show simple item record

dc.contributor.advisor McCarthy, Florence O. Miller, Charlotte M. 2012-02-23T16:51:21Z 2016-02-24T05:00:08Z 2011-12 2012-02-20
dc.identifier.citation Miller, C. M., 2011. Design, Synthesis and Evaluation of Novel Ellipticine Derivatives and Analogues as Anti-Cancer Agents. PhD Thesis, University College Cork. en
dc.description.abstract This thesis describes work carried out on the synthesis of novel 5- and 11-substituted ellipticines and derivatives of the ellipticine analogues, isoellipticine and deazaellipticine, followed by investigation of their potential as anti-cancer agents. Preparation of the key 5- and 11-substituted ellipticine targets involved the development of regiospecific, sequential alkylation reactions with alkenyllithium and Grignard reagents. Investigation of these novel reactions resulted in a new route towards 5-substituted ellipticines via Grignard reaction with vinylmagnesium bromide. These novel 5-vinylellipticine derivatives were further functionalised in an ozonolysis reaction, followed by oxidation to give a range of novel 5-substituted ellipticines. Less success was encountered in the 11-substituted ellipticine series, however preparation of these derivatives using a previously published route was accomplished, and the resulting 11-formylellipticine was further derivatised to give a panel of novel 9- and 11-substituted ellipticines, incorporating amide, carboxylate, imine and amine functionality. The successful route towards 5-substituted ellipticines was applied to the preparation of a range of novel 11-substituted isoellipticines and 6-substituted deazaellipticines, the first time substantial synthesis has been undertaken with these analogues. In addition to this, the first preparation of isoellipticinium salts is described, and a panel of novel isoellipticinium, 7 formylisoellipticinium and 7-hydroxyisoellipticinium salts were synthesised in good yields. Biological evaluation of a panel of 43 novel ellipticine, isoellipticine and deazaellipticine derivatives was accomplished with a topoisomerase II decatenation assay and submission to the NCI 60-cell line screen. Four novel isoellipticine topoisomerase II inhibitors were identified from the decatenation assay, with strong activity at 10 μM. In addition to this, NCI screening identified five highly cytotoxic ellipticine and isoellipticine compounds with remarkable selectivity profiles for different cancer types. These novel lead compounds represent new templates for further research and synthesis. en
dc.description.sponsorship Higher Education Authority (PRTLI cycle 4, Biopharmaceutical & Pharmacological Sciences Program) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher University College Cork en
dc.rights © 2011, Charlotte Miller en
dc.rights.uri en
dc.subject Ellipticine en
dc.subject Anti-cancer en
dc.subject Topoisomerase inhibitor en
dc.subject Organic synthesis en
dc.subject.lcsh Antineoplastic agents--Development en
dc.subject.lcsh Enzyme inhibitors en
dc.subject.lcsh Drugs--Design en
dc.subject.lcsh Cancer--Chemotherapy en
dc.subject.lcsh Organic compounds--Synthesis en
dc.title Design, synthesis and evaluation of novel ellipticine derivatives and analogues as anti-cancer agents en
dc.type Doctoral thesis en
dc.type.qualificationlevel Doctoral en
dc.type.qualificationname PhD (Chemistry) en
dc.internal.availability Full text available en This thesis has been partially restricted until 23 February 2016. Chapter 2 (pp.43 - 98), Chapters 4 - 7 and Appendices (pp. 107 - 350)are currently unavailable. en
dc.description.version Accepted Version en
dc.contributor.funder Higher Education Authority en
dc.description.status Not peer reviewed en Chemistry en

Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2011, Charlotte Miller Except where otherwise noted, this item's license is described as © 2011, Charlotte Miller
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement